Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Deals

Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence

Fineline Cube Jul 22, 2024

Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with...

Company Deals

MedSci Healthcare’s Bioon.com Partners with Wego Group to Boost Local Innovation and Product Promotion

Fineline Cube Jul 22, 2024

MedSci Healthcare Co., Ltd (HKG: 2415), a Chinese healthcare company, has announced that its subsidiary,...

Company Deals

Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies

Fineline Cube Jul 22, 2024

Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a...

Company Deals

Huadong Medicine to Expand TCM Footprint with Acquisition of Hengba Pharmaceutical

Fineline Cube Jul 22, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced its intention to...

Company Deals

Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech

Fineline Cube Jul 22, 2024

Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over...

Company Deals

BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia

Fineline Cube Jul 22, 2024

Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE:...

Company Deals Drug

Apeiron Therapeutics Sells Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for USD 30 Million

Fineline Cube Jul 22, 2024

Apeiron Therapeutics, a Shanghai-based biopharmaceutical company, has reached an agreement to sell all rights to...

Company Deals Digital Hospital

WeDoctor Partners with Shanghai Children’s Medical Center to Enhance Pediatric Care

Fineline Cube Jul 22, 2024

WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700)...

Company Drug

Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA

Fineline Cube Jul 22, 2024

Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...

Company

Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase

Fineline Cube Jul 19, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...

Company Deals Drug

J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure

Fineline Cube Jul 19, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...

Company

Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales

Fineline Cube Jul 19, 2024

Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its...

Company Drug

Sino Biopharmaceutical Submits Market Approval Filing for CDK2/4/6 Inhibitor Culmerciclib in Breast Cancer

Fineline Cube Jul 19, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced the submission...

Company Drug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management

Fineline Cube Jul 19, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...

Hospital Policy / Regulatory R&D

China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing

Fineline Cube Jul 19, 2024

China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome...

Company Drug

China’s NMPA Suspends Daewoong Bio’s Cefodizime Over Inspection Refusal

Fineline Cube Jul 19, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Drug

Bain Capital-Backed Tenacia Wins NMPA Approval for Ganaxolone Oral Suspension for CDKL5 Deficiency

Fineline Cube Jul 19, 2024

Tenacia, a central nervous system (CNS) specialist company incubated by Bain Capital, has announced that...

Company Medical Device

MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval

Fineline Cube Jul 19, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Medical Device

Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach

Fineline Cube Jul 19, 2024

Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers

Fineline Cube Jul 19, 2024

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...

Posts pagination

1 … 273 274 275 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.